{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:39:00Z","timestamp":1788914340087,"version":"build-2803163510"},"reference-count":66,"publisher":"American Association for Cancer Research (AACR)","issue":"4","funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1016701"],"award-info":[{"award-number":["1016701"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["109220"],"award-info":[{"award-number":["109220"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08 CA237627"],"award-info":[{"award-number":["K08 CA237627"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R50 CA211447-06A1"],"award-info":[{"award-number":["R50 CA211447-06A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA280116"],"award-info":[{"award-number":["R01 CA280116"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Despite advances in understanding the genetic abnormalities in myeloproliferative neoplasms (MPN) and the development of JAK2 inhibitors, there is an urgent need to devise new treatment strategies, particularly for patients with triple-negative (TN) myelofibrosis (MF) who lack mutations in the JAK2 kinase pathway and have very poor clinical outcomes. Here we report that MYC copy number gain and increased MYC expression frequently occur in TN-MF and that MYC-directed activation of S100A9, an alarmin protein that plays pivotal roles in inflammation and innate immunity, is necessary and sufficient to drive development and progression of MF. Notably, the MYC-S100A9 circuit provokes a complex network of inflammatory signaling that involves numerous hematopoietic cell types in the bone marrow microenvironment. Accordingly, genetic ablation of S100A9 or treatment with small molecules targeting the MYC-S100A9 pathway effectively ameliorates MF phenotypes, highlighting the MYC\u2013alarmin axis as a novel therapeutic vulnerability for this subgroup of MPNs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study establishes that MYC expression is increased in TN-MPNs via trisomy 8, that a MYC-S100A9 circuit manifest in these cases is sufficient to provoke myelofibrosis and inflammation in diverse hematopoietic cell types in the BM niche, and that the MYC-S100A9 circuit is targetable in TN-MPNs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0210","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T09:38:07Z","timestamp":1715074687000},"page":"276-297","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC\u2013Alarmin Axis"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-6781","authenticated-orcid":false,"given":"Nicole D.","family":"Vincelette","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-9372","authenticated-orcid":false,"given":"Xiaoqing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Moffitt Cancer Center & Research Institute, Tampa, Florida. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-7415","authenticated-orcid":false,"given":"Andrew T.","family":"Kuykendall","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5150-5817","authenticated-orcid":false,"given":"Jungwon","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4488-5151","authenticated-orcid":false,"given":"Siyuan","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Illinois Chicago, Chicago, Illinois. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1832-4823","authenticated-orcid":false,"given":"Chia-Ho","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Moffitt Cancer Center & Research Institute, Tampa, Florida. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3015-0846","authenticated-orcid":false,"given":"Rinzine","family":"Sammut","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida. 1"},{"name":"D\u00e9partement d\u2019H\u00e9matologie Clinique, Centre Hospitalier Universitaire de Nice, Nice, France. 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5666-8575","authenticated-orcid":false,"given":"Tiffany N.","family":"Razabdouski","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-5960","authenticated-orcid":false,"given":"Hai V.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4458-7192","authenticated-orcid":false,"given":"Erika A.","family":"Eksioglu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Moffitt Cancer Center & Research Institute, Tampa, Florida. 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2872-1961","authenticated-orcid":false,"given":"Onyee","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1509-6319","authenticated-orcid":false,"given":"Najla","family":"Al Ali","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-1029","authenticated-orcid":false,"given":"Parth C.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida. 1"},{"name":"Department of Internal Medicine, University of South Florida, Tampa, Florida. 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-0404","authenticated-orcid":false,"given":"Dae H.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Science, Department of Internal Medicine, University of South Florida, Tampa, Florida 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2408-0095","authenticated-orcid":false,"given":"Shima","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Tumor Microenvironment & Metastasis, Moffitt Cancer Center & Research Institute, Tampa, Florida. 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-659X","authenticated-orcid":false,"given":"Renan B.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery, Moffitt Cancer Center & Research Institute, Tampa, Florida. 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0150-444X","authenticated-orcid":false,"given":"Elizabeth","family":"Hyjek","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Moffitt Cancer Center & Research Institute, Tampa, Florida. 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0021-7694","authenticated-orcid":false,"given":"Qianxing","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Moffitt Cancer Center & Research Institute, Tampa, Florida. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6818-3451","authenticated-orcid":false,"given":"Suzanne","family":"Cory","sequence":"additional","affiliation":[{"name":"The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9263-7775","authenticated-orcid":false,"given":"Harshani R.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery, Moffitt Cancer Center & Research Institute, Tampa, Florida. 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-1458","authenticated-orcid":false,"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Moffitt Cancer Center & Research Institute, Tampa, Florida. 11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-5468","authenticated-orcid":false,"given":"Daniel J.","family":"Murphy","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. 12"},{"name":"Cancer Research UK Scotland Institute, Glasgow, United Kingdom. 13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3958-5475","authenticated-orcid":false,"given":"Daesung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Illinois Chicago, Chicago, Illinois. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-7145","authenticated-orcid":false,"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota. 14"},{"name":"Department of Oncology, Mayo Clinic, Rochester, Minnesota. 15"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7561-9065","authenticated-orcid":false,"given":"John L.","family":"Cleveland","sequence":"additional","affiliation":[{"name":"Department of Tumor Microenvironment & Metastasis, Moffitt Cancer Center & Research Institute, Tampa, Florida. 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-1635","authenticated-orcid":false,"given":"Seongseok","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, Tampa, Florida. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"2026041310144183800_bib1","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"key":"2026041310144183800_bib2","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"key":"2026041310144183800_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","article-title":"JAK\u2013STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","volume":"5","author":"Kleppe","year":"2015","journal-title":"Cancer Discov"},{"key":"2026041310144183800_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"2026041310144183800_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"2026041310144183800_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026041310144183800_bib7","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026041310144183800_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"2026041310144183800_bib9","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1182\/blood-2021-151978","article-title":"Triple-negative myelofibrosis: disease features, response to treatment and outcomes","volume":"138","author":"Aguirre","year":"2021","journal-title":"Blood"},{"key":"2026041310144183800_bib10","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"2026041310144183800_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"2026041310144183800_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/318533a0","article-title":"The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice","volume":"318","author":"Adams","year":"1985","journal-title":"Nature"},{"key":"2026041310144183800_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/2643-3230.BCD-20-0029","article-title":"TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia","volume":"2","author":"Yun","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"2026041310144183800_bib14","doi-asserted-by":"crossref","first-page":"106733","DOI":"10.1016\/j.leukres.2021.106733","article-title":"MYC overexpression is associated with an early disease progression from MDS to AML","volume":"111","author":"Gajzer","year":"2021","journal-title":"Leuk Res"},{"key":"2026041310144183800_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10428194.2018.1464158","article-title":"MYC protein expression is an important prognostic factor in acute myeloid leukemia","volume":"60","author":"Ohanian","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2026041310144183800_bib16","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood-2006-01-030643","article-title":"CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins","volume":"109","author":"Sloand","year":"2006","journal-title":"Blood"},{"key":"2026041310144183800_bib17","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood-2005-02-0734","article-title":"c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations","volume":"106","author":"Luo","year":"2005","journal-title":"Blood"},{"key":"2026041310144183800_bib18","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood.2020006374","article-title":"MYC-induced human acute myeloid leukemia requires a continuing IL-3\/GM-CSF costimulus","volume":"136","author":"Bulaeva","year":"2020","journal-title":"Blood"},{"key":"2026041310144183800_bib19","doi-asserted-by":"crossref","first-page":"106194","DOI":"10.1016\/j.leukres.2019.106194","article-title":"Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC)","volume":"84","author":"Yun","year":"2019","journal-title":"Leuk Res"},{"key":"2026041310144183800_bib20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00277-008-0483-y","article-title":"Cytogenetic features in myelodysplastic syndromes","volume":"87","author":"Haase","year":"2008","journal-title":"Ann Hematol"},{"key":"2026041310144183800_bib21","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","article-title":"Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"2026041310144183800_bib22","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2026041310144183800_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"2026041310144183800_bib24","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.18632\/oncotarget.1951","article-title":"Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance","volume":"5","author":"Huang","year":"2014","journal-title":"Oncotarget"},{"key":"2026041310144183800_bib25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1101\/gad.307504.117","article-title":"JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias","volume":"32","author":"Kim","year":"2018","journal-title":"Genes Dev"},{"key":"2026041310144183800_bib26","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.stem.2020.11.004","article-title":"Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis","volume":"28","author":"Leimk\u00fchler","year":"2021","journal-title":"Cell Stem Cell"},{"key":"2026041310144183800_bib27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.stem.2016.08.021","article-title":"Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia","volume":"19","author":"Zambetti","year":"2016","journal-title":"Cell Stem Cell"},{"key":"2026041310144183800_bib28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrc3893","article-title":"S100 proteins in cancer","volume":"15","author":"Bresnick","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2026041310144183800_bib29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41375-020-0997-4","article-title":"Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)","volume":"35","author":"Yun","year":"2021","journal-title":"Leukemia"},{"key":"2026041310144183800_bib30","doi-asserted-by":"crossref","first-page":"eaao2565","DOI":"10.1126\/scitranslmed.aao2565","article-title":"The ERBB network facilitates KRAS-driven lung tumorigenesis","volume":"10","author":"Kruspig","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026041310144183800_bib31","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/blood-2006-01-0172","article-title":"MYC levels govern hematopoietic tumor type and latency in transgenic mice","volume":"108","author":"Smith","year":"2006","journal-title":"Blood"},{"key":"2026041310144183800_bib32","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1038\/sj.onc.1208399","article-title":"T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC","volume":"24","author":"Smith","year":"2005","journal-title":"Oncogene"},{"key":"2026041310144183800_bib33","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"2026041310144183800_bib34","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s00277-021-04615-8","article-title":"Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells","volume":"100","author":"Baumeister","year":"2021","journal-title":"Ann Hematol"},{"key":"2026041310144183800_bib35","doi-asserted-by":"crossref","first-page":"e0135463","DOI":"10.1371\/journal.pone.0135463","article-title":"Microarray and proteomic analyses of myeloproliferative neoplasms with a highlight on the mTOR signaling pathway","volume":"10","author":"\u010coki\u0107","year":"2015","journal-title":"PLoS One"},{"key":"2026041310144183800_bib36","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1186\/ar1939","article-title":"The S100A8\/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis","volume":"8","author":"Sunahori","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2026041310144183800_bib37","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1189\/jlb.2A0415-170RRR","article-title":"CD68 on rat macrophages binds tightly to S100A8 and S100A9 and helps to regulate the cells\u2019 immune functions","volume":"100","author":"Okada","year":"2016","journal-title":"J Leukoc Biol"},{"key":"2026041310144183800_bib38","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1084\/jem.20080132","article-title":"Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein","volume":"205","author":"Cheng","year":"2008","journal-title":"J Exp Med"},{"key":"2026041310144183800_bib39","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","article-title":"Randomized, double-blind, placebo-controlled phase III study of Tasquinimod in men with metastatic castration-resistant prostate cancer","volume":"34","author":"Sternberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026041310144183800_bib40","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer Cell"},{"key":"2026041310144183800_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"key":"2026041310144183800_bib42","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"2026041310144183800_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12915-021-00955-z","article-title":"Single-cell RNA-seq reveals a concomitant delay in differentiation and cell cycle of aged hematopoietic stem cells","volume":"19","author":"H\u00e9rault","year":"2021","journal-title":"BMC Biol"},{"key":"2026041310144183800_bib44","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1101\/gad.313104","article-title":"c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation","volume":"18","author":"Wilson","year":"2004","journal-title":"Genes Dev"},{"key":"2026041310144183800_bib45","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood-2009-01-197947","article-title":"c-Myc\u2013mediated control of cell fate in megakaryocyte-erythrocyte progenitors","volume":"114","author":"Guo","year":"2009","journal-title":"Blood"},{"key":"2026041310144183800_bib46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1097-2765(00)80367-6","article-title":"Reversible tumorigenesis by MYC in hematopoietic lineages","volume":"4","author":"Felsher","year":"1999","journal-title":"Mol Cell"},{"key":"2026041310144183800_bib47","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","article-title":"Macrophage polarization: different gene signatures in M1(LPS+) vs. Classically and M2(LPS\u2013) vs. Alternatively activated macrophages","volume":"10","author":"Orecchioni","year":"2019","journal-title":"Front Immunol"},{"key":"2026041310144183800_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00277-020-04304-y","article-title":"Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm","volume":"100","author":"Molitor","year":"2021","journal-title":"Ann Hematol"},{"key":"2026041310144183800_bib49","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2018-09-876615","article-title":"Vitamin D receptor\u2013mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis","volume":"133","author":"Wakahashi","year":"2019","journal-title":"Blood"},{"key":"2026041310144183800_bib50","doi-asserted-by":"crossref","first-page":"e52844","DOI":"10.1371\/journal.pone.0052844","article-title":"Critical roles of myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant","volume":"8","author":"Funakoshi-Tago","year":"2013","journal-title":"PLoS One"},{"key":"2026041310144183800_bib51","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2007-07-102186","article-title":"The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes","volume":"111","author":"Wernig","year":"2008","journal-title":"Blood"},{"key":"2026041310144183800_bib52","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/ncb3530","article-title":"Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis","volume":"19","author":"Decker","year":"2017","journal-title":"Nat Cell Biol"},{"key":"2026041310144183800_bib53","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.stem.2017.03.008","article-title":"Gli1+ mesenchymal stromal cells are a key driver of bone marrow fibrosis and an important cellular therapeutic target","volume":"20","author":"Schneider","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2026041310144183800_bib54","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2018-02-834820","article-title":"The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis","volume":"131","author":"Kramann","year":"2018","journal-title":"Blood"},{"key":"2026041310144183800_bib55","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2010.10.002","article-title":"CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation","volume":"18","author":"Rakhra","year":"2010","journal-title":"Cancer Cell"},{"key":"2026041310144183800_bib56","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","article-title":"Myc cooperates with Ras by programming inflammation and immune suppression","volume":"171","author":"Kortlever","year":"2017","journal-title":"Cell"},{"key":"2026041310144183800_bib57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"2026041310144183800_bib58","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"2026041310144183800_bib59","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pbio.1000097","article-title":"Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides","volume":"7","author":"Bj\u00f6rk","year":"2009","journal-title":"PLoS Biol"},{"key":"2026041310144183800_bib60","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-020-2430-6","article-title":"Monogenic and polygenic inheritance become instruments for clonal selection","volume":"584","author":"Loh","year":"2020","journal-title":"Nature"},{"key":"2026041310144183800_bib61","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"2026041310144183800_bib62","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1016\/j.clml.2017.07.166","article-title":"Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)","volume":"17","author":"Yun","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"2026041310144183800_bib63","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1182\/blood-2015-02-629485","article-title":"4EBP1\/c-MYC\/PUMA and NF\u03baB\/EGR1\/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells","volume":"127","author":"Yun","year":"2016","journal-title":"Blood"},{"key":"2026041310144183800_bib64","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s42003-020-01463-6","article-title":"Transfer learning efficiently maps bone marrow cell types from mouse to human using single-cell RNA sequencing","volume":"3","author":"Stumpf","year":"2020","journal-title":"Commun Biol"},{"key":"2026041310144183800_bib65","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"key":"2026041310144183800_bib66","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.cell.2018.03.074","article-title":"Integrated single-cell analysis maps the continuous regulatory landscape of human hematopoietic differentiation","volume":"173","author":"Buenrostro","year":"2018","journal-title":"Cell"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0210\/3451455\/bcd-23-0210.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0210\/3461570\/bcd-23-0210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/4\/276\/3470431\/bcd-23-0210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/4\/276\/3470431\/bcd-23-0210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:15:05Z","timestamp":1776089705000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/4\/276\/746109\/Trisomy-8-Defines-a-Distinct-Subtype-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":66,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,5,7]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0210","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.26134488.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134476.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134479.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134485.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134482","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134482.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134485","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134476","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134488","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.26134479","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7309458","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.c.7309458.v1","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]}}}